Actonel drug is an inhibitor of bone resorption in osteoporosis.
Effect of the drug due to its composition of active ingredient.
Risedronic acid is a pyridine bisphosphonate that bind to the hydroxyapatite crystals of bone tissue. Effect of risedronic acid on the bone turnover associated with the inhibition of osteoclasts and reduction of bone resorption mediated by them. At the same time the activity of osteoblasts and bone mineralization process is preserved. In the application of risedronic acid dose-dependently bone density increased, and its biomechanical properties are improved. The inhibition of bone resorption of risedronic acid is reversible and ceases after discontinuation of the drug.
Already after one month of receipt of risedronic acid, a decrease in levels of biochemical markers of bone turnover, which is maximized after 3-6 months of treatment.
After 12 months of taking the pills Actonel 35 mg 1 time per week and tablets Actonel 5 mg daily clinical effect and reduction of biochemical markers of bone turnover were similar.
Risedronic acid reduces the risk of compression fractures of the vertebral body and proximal femur in osteoporosis of women and in postmenopausal in men and women, who take glucocorticosteroid drugs for systemic effects for long-term. In addition, it slows down the rate of decline in growth in women with postmenopausal osteoporosis. Bone formed within 2-3 years of treatment by risedronic acid, has conventional plate structure and normal level of mineralization.
Indications for use:
The drug Actonel is indicated for the treatment of osteoporosis in women in postmenopausal to prevent fractures, including vertebral fractures and hip; treatment of osteoporosis in men for the prevention of fracture.
Mode of application:
Actonel drug is ingested inside. The recommended dose for adults is 1 tablet of Actonel 35 mg 1 time per week (it is always taken at the same day of the week).
Absorption of the drug is significantly affected by food, however tablet Actonel 35 mg should be taken in the morning for at least 30 minutes before the first ingestion of food or beverages (except for drinking water), and other drugs at that day.
Most of adverse effects have mild and moderate severity and usually did not require discontinuation of treatment.
On the part of the central nervous system: often: headache, dizziness, fatigue, depression, insomnia.
On the part of the eye: infrequent: acute iritis.
On the gastrointestinal tract: often: constipation, dyspepsia, nausea, abdominal pain, diarrhea; rare: gastritis, esophagitis, dysphagia, duodenitis, esophageal ulcer; rare: glossitis, esophageal stricture.
On the part of the musculoskeletal system and connective tissue disorders: often: musculoskeletal pain.
On the side of the functional state of the hepatic: rare: deviations from the norm of the functional state of the hepatic.
On the eyes: uveitis (inflammation of the uvea).
On the part of the musculoskeletal system and connective tissue disorders: osteonecrosis of the upper and / or lower jaw.
Cases of osteonecrosis of the mandible and maxilla mainly in cancer patients on the background of anti-tumor treatment including bisphosphonates. Risk factors for the development of osteonecrosis are cancer, chemotherapy, radiation therapy, corticosteroids, poor oral hygiene, local infection-inflammation processes, including osteomyelitis. In most reported cases patients during treatment with bisphosphonates was conducted tooth extraction. The causal relationship of osteonecrosis of the upper and lower jaw with bisphosphonates remains is unclear.
Skin reactions: very rare: allergic and skin reactions, including angioedema, generalized rash and bullous skin reactions, sometimes severe ones.
Other: infection (including urinary tract), increased blood pressure.